Safety and feasibility of intramedullary injected bone marrow–derived mesenchymal stem cells in acute complete spinal cord injury: phase 1 trial

View More View Less
  • 1 Stem Cell & Translational Neurosciences Laboratory, Department of Neurosurgery, JPNA Trauma Center, All India Institute of Medical Sciences, New Delhi, India; and
  • | 2 University College of Medical Sciences and GTB Hospital, Dilshad Garden, Delhi, India
Restricted access

Purchase Now

USD  $45.00

Spine - 1 year subscription bundle (Individuals Only)

USD  $376.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
USD  $45.00
USD  $376.00
USD  $612.00
Print or Print + Online Sign in

OBJECTIVE

The intramedullary route holds the potential to provide the most concentration of stem cells in cases of spinal cord injury (SCI). However, the safety and feasibility of this route need to be studied in human subjects. The aim of this study was to evaluate the safety and feasibility of intramedullary injected bone marrow–derived mesenchymal stem cells (BM-MSCs) in acute complete SCI.

METHODS

In this prospective study conducted over a 2-year period, 27 patients with acute (defined as within 1 week of injury) and complete SCI were randomized to receive BM-MSC or placebo through an intramedullary route intraoperatively at the time of spinal decompression and fusion. Institutional ethics approval was obtained, and informed consent was obtained from all patients. Safety was assessed using laboratory and clinicoradiological parameters preoperatively and 3 and 6 months after surgery.

RESULTS

A total of 180 patients were screened during the study period. Of these, 27 were enrolled in the study. Three patients withdrew, 3 patients were lost to follow-up, and 8 patients died, leaving a total of 13 patients for final analysis. Seven of these patients were in the stem cell group, and 6 were in the control group. Both groups were well matched in terms of sex, age, and weight. No adverse events related to stem cell injection were noted for laboratory and radiological parameters. Five patients in the control group and 3 patients in the stem cell group died during the follow-up period.

CONCLUSIONS

Intramedullary injection of BM-MSCs was found to be safe and feasible for use in patients with acute complete SCI.

ABBREVIATIONS

BM-MSC = bone marrow–derived mesenchymal stem cell; SCI = spinal cord injury.

Illustration from Dibble et al. (pp 384–394). © Washington University Department of Neurosurgery, published with permission.

Spine - 1 year subscription bundle (Individuals Only)

USD  $376.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
USD  $376.00
USD  $612.00
  • 1

    World Health Organization. International perspectives on spinal cord injury. 2013.Accessed February 23, 2022. https://www.who.int/publications/i/item/international-perspectives-on-spinal-cord-injury

    • Search Google Scholar
    • Export Citation
  • 2

    Bracken MB. Methylprednisolone in the management of acute spinal cord injuries. Med J Aust. 1990;153(6):368.

  • 3

    Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med. 1990;322(20):14051411.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4

    Geisler FH, Coleman WP, Grieco G, Poonian D. The Sygen multicenter acute spinal cord injury study. Spine (Phila Pa 1976). 2001;26(24 Suppl):S87S98.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5

    Vaccaro AR, Daugherty RJ, Sheehan TP, et al. Neurologic outcome of early versus late surgery for cervical spinal cord injury. Spine (Phila Pa 1976). 1997;22(22):26092613.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6

    Cardenas DD, Ditunno J, Graziani V, et al. Phase 2 trial of sustained-release fampridine in chronic spinal cord injury. Spinal Cord. 2007;45(2):158168.

  • 7

    Garbossa D, Fontanella M, Fronda C, et al. New strategies for repairing the injured spinal cord: the role of stem cells. Neurol Res. 2006;28(5):500504.

  • 8

    Keirstead HS, Nistor G, Bernal G, et al. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. J Neurosci. 2005;25(19):46944705.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9

    Popa ER, Harmsen MC, Tio RA, et al. Circulating CD34+ progenitor cells modulate host angiogenesis and inflammation in vivo. J Mol Cell Cardiol. 2006;41(1):8696.

  • 10

    Anderson KD. Targeting recovery: priorities of the spinal cord-injured population. J Neurotrauma. 2004;21(10):13711383.

  • 11

    Lima C, Escada P, Pratas-Vital J, et al. Olfactory mucosal autografts and rehabilitation for chronic traumatic spinal cord injury. Neurorehabil Neural Repair. 2010;24(1):1022.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12

    Saberi H, Firouzi M, Habibi Z, et al. Safety of intramedullary Schwann cell transplantation for postrehabilitation spinal cord injuries: 2-year follow-up of 33 cases. J Neurosurg Spine. 2011;15(5):515525.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13

    Jeon SR, Park JH, Lee JH, et al. Treatment of spinal cord injury with bone marrow-derived, cultured autologous mesenchymal stem cells. Tissue Eng Regen Med. 2010;7(3):316322.

    • Search Google Scholar
    • Export Citation
  • 14

    Park JH, Kim DY, Sung IY, et al. Long-term results of spinal cord injury therapy using mesenchymal stem cells derived from bone marrow in humans. Neurosurgery. 2012;70(5):12381247.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15

    Deng YB, Liu XG, Liu ZG, Liu XL, Liu Y, Zhou GQ. Implantation of BM mesenchymal stem cells into injured spinal cord elicits de novo neurogenesis and functional recovery: evidence from a study in rhesus monkeys. Cytotherapy. 2006;8(3):210214.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16

    Syková E, Homola A, Mazanec R, et al. Autologous bone marrow transplantation in patients with subacute and chronic spinal cord injury. Cell Transplant. 2006;15(8-9):675687.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17

    Geffner LF, Santacruz P, Izurieta M, et al. Administration of autologous bone marrow stem cells into spinal cord injury patients via multiple routes is safe and improves their quality of life: comprehensive case studies. Cell Transplant. 2008;17(12):12771293.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18

    Park HC, Shim YS, Ha Y, et al. Treatment of complete spinal cord injury patients by autologous bone marrow cell transplantation and administration of granulocyte-macrophage colony stimulating factor. Tissue Eng. 2005;11(5-6):913922.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19

    Yoon SH, Shim YS, Park YH, et al. Complete spinal cord injury treatment using autologous bone marrow cell transplantation and bone marrow stimulation with granulocyte macrophage-colony stimulating factor: phase I/II clinical trial. Stem Cells. 2007;25(8):20662073.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20

    Kumar AA, Kumar SR, Narayanan R, Arul K, Baskaran M. Autologous bone marrow derived mononuclear cell therapy for spinal cord injury: a phase I/II clinical safety and primary efficacy data. Exp Clin Transplant. 2009;7(4):241248.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21

    Samijn JP, te Boekhorst PA, Mondria T, et al. Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis. J Neurol Neurosurg Psychiatry. 2006;77(1):4650.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22

    Cristante AF, Barros-Filho TE, Tatsui N, et al. Stem cells in the treatment of chronic spinal cord injury: evaluation of somatosensitive evoked potentials in 39 patients. Spinal Cord. 2009;47(10):733738.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23

    Deda H, Inci MC, Kürekçi AE, et al. Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up. Cytotherapy. 2009;11(1):1825.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24

    Akiyama Y, Radtke C, Kocsis JD. Remyelination of the rat spinal cord by transplantation of identified bone marrow stromal cells. J Neurosci. 2002;22(15):66236630.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25

    Takeuchi H, Natsume A, Wakabayashi T, et al. Intravenously transplanted human neural stem cells migrate to the injured spinal cord in adult mice in an SDF-1- and HGF-dependent manner. Neurosci Lett. 2007;426(2):6974.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 26

    Urdzíková L, Jendelová P, Glogarová K, Burian M, Hájek M, Syková E. Transplantation of bone marrow stem cells as well as mobilization by granulocyte-colony stimulating factor promotes recovery after spinal cord injury in rats. J Neurotrauma. 2006;23(9):13791391.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27

    Vaquero J, Zurita M, Oya S, Santos M. Cell therapy using bone marrow stromal cells in chronic paraplegic rats: systemic or local administration?. Neurosci Lett. 2006;398(1-2):129134.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 28

    Himes BT, Neuhuber B, Coleman C, et al. Recovery of function following grafting of human bone marrow-derived stromal cells into the injured spinal cord. Neurorehabil Neural Repair. 2006;20(2):278296.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29

    Karimi-Abdolrezaee S, Eftekharpour E, Wang J, Morshead CM, Fehlings MG. Delayed transplantation of adult neural precursor cells promotes remyelination and functional neurological recovery after spinal cord injury. J Neurosci. 2006;26(13):33773389.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30

    Parr AM, Kulbatski I, Tator CH. Transplantation of adult rat spinal cord stem/progenitor cells for spinal cord injury. J Neurotrauma. 2007;24(5):835845.

  • 31

    Pal R, Gopinath C, Rao NM, et al. Functional recovery after transplantation of bone marrow-derived human mesenchymal stromal cells in a rat model of spinal cord injury. Cytotherapy. 2010;12(6):792806.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 32

    Yagi H, Soto-Gutierrez A, Parekkadan B, et al. Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplant. 2010;19(6):667679.

  • 33

    Zieker D, Schäfer R, Glatzle J, et al. Lactate modulates gene expression in human mesenchymal stem cells. Langenbecks Arch Surg. 2008;393(3):297301.

  • 34

    McColgan P, Sharma P, Bentley P. Stem cell tracking in human trials: a meta-regression. Stem Cell Rev Rep. 2011;7(4):10311040.

  • 35

    Pal R, Venkataramana NK, Bansal A, et al. Ex vivo-expanded autologous bone marrow-derived mesenchymal stromal cells in human spinal cord injury/paraplegia: a pilot clinical study. Cytotherapy. 2009;11(7):897911.

    • PubMed
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 1222 1222 237
Full Text Views 189 189 119
PDF Downloads 210 210 108
EPUB Downloads 0 0 0